https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21794 9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7789 Sat 24 Mar 2018 08:39:20 AEDT ]]> Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]> Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29325 Sat 24 Mar 2018 07:34:20 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]> Oncology and radiation oncology awareness in final year medical students in Australia and New Zealand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46205 Mon 14 Nov 2022 11:29:52 AEDT ]]> Junior Doctor Evaluation of Radiation Oncology Education and Training in Medical Schools and Prevocational Training in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44209 Mon 10 Oct 2022 15:49:45 AEDT ]]> Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38069 Fri 12 Nov 2021 12:17:35 AEDT ]]> The status of radiation oncology teaching in Australian and New Zealand medical schools https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41774 Fri 12 Aug 2022 11:56:45 AEST ]]>